Rx-360 Summary of FDA Draft Guidance for Industry, Development and Submission of Near Infrared Analytical Procedures
Rx-360 has produced a summary of FDA's draft guidance for industry, Development and Submission of Near Infrared Analytical Procedures.
Near infrared (NIR) analytical procedures are increasingly being used in the pharmaceutical industry for the identification and assay of pharmaceutical starting materials, intermediates and finished products. They are also used to monitor and control manufacturing processes. The development and validation of NIR analytical procedures are therefore important for ensuring the quality of pharmaceuticals. It is important for manufacturers who use such procedures to understand the factors that can affect the performance and suitability of the procedures and the approaches that can be used to validate them.
This guidance provides recommendations to applicants of new drug applications (NDAs), abbreviated new drug applications (ANDAs) and drug master file (DMF) holders regarding the development and submission of NIR analytical procedures used during the manufacture and analysis of pharmaceuticals (including raw materials, in-process materials and intermediates, and finished products). It also provides recommendations regarding how the concepts described in the International Conference on Harmonization (ICH) guidance for industry Q2(R1) Validation of Analytical Procedures: Text and Methodology (ICH Q2(R1)) and PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance can be applied to the development, validation, and submission of NIR analytical procedures.
This guidance only pertains to the development and validation of NIR analytical procedures and does not provide recommendations concerning the set-up and qualification of NIR instruments or their maintenance and calibration. Although this guidance is written specifically for NIR, the fundamental concepts of validation can be applied to other PAT technologies including Raman, focused beam reflection measurement, particle imaging, X-ray, among other techniques.
Comments on the draft guidance are due by 1 June 2015.
Related News
-
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News US FDA grants priority review for Eisai and Biogen's Alzheimer's drug
Decision by US drug regulator on lecanemab expected by early next year -
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPHI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPHI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance